These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34497355)

  • 1. In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.
    Shan L; Dyk NV; Haskins N; Cook KM; Rosenthal KL; Mazor R; Dragulin-Otto S; Jiang Y; Wu H; Dall'Acqua WF; Borrok MJ; Damschroder MM; Oganesyan V
    Commun Biol; 2021 Sep; 4(1):1048. PubMed ID: 34497355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
    Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
    MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics.
    Ishino T; Wang M; Mosyak L; Tam A; Duan W; Svenson K; Joyce A; O'Hara DM; Lin L; Somers WS; Kriz R
    J Biol Chem; 2013 Jun; 288(23):16529-16537. PubMed ID: 23615911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dual Targeting of FcRn and FcγRs
    Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
    Front Immunol; 2021; 12():728322. PubMed ID: 34512662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
    Dumont JA; Low SC; Peters RT; Bitonti AJ
    BioDrugs; 2006; 20(3):151-60. PubMed ID: 16724863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.
    Bajardi-Taccioli A; Blum A; Xu C; Sosic Z; Bergelson S; Feschenko M
    Mol Immunol; 2015 Oct; 67(2 Pt B):616-24. PubMed ID: 26254986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
    Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
    J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
    Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
    MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations.
    Huang X; Zheng F; Zhan CG
    Mol Biosyst; 2013 Dec; 9(12):3047-58. PubMed ID: 24057047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative methods for developing Fc mutants with extended half-lives.
    Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
    Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
    Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
    MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.
    Patel DA; Puig-Canto A; Challa DK; Perez Montoyo H; Ober RJ; Ward ES
    J Immunol; 2011 Jul; 187(2):1015-22. PubMed ID: 21690327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
    Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
    MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.